Search details
1.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-35139274
2.
The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Lab Invest
; 104(3): 100303, 2024 03.
Article
in English
| MEDLINE | ID: mdl-38103870
3.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Article
in English
| MEDLINE | ID: mdl-32101663
4.
Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
Mod Pathol
; 36(4): 100056, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36788078
5.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37526149
6.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34860318
7.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(4): 499-511, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33676601
8.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34264439
9.
Hope, bias and survival expectations of advanced cancer patients: A cross-sectional study.
Psychooncology
; 30(5): 780-788, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33739561
10.
Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
N Engl J Med
; 386(18): 1771-1772, 2022 05 05.
Article
in English
| MEDLINE | ID: mdl-35507498
11.
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer.
Curr Opin Oncol
; 32(6): 575-584, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32852307
12.
Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.
Breast Cancer Res Treat
; 178(2): 295-305, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31410680
13.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Future Oncol
; 15(17): 1951-1961, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30977385
14.
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
N Engl J Med
; 382(26): e108, 2020 06 25.
Article
in English
| MEDLINE | ID: mdl-32579835
15.
Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
Breast Cancer Res Treat
; 168(3): 713-721, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29313215
16.
Cost of Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS): prospective cohort study protocol.
BMC Cancer
; 18(1): 459, 2018 04 23.
Article
in English
| MEDLINE | ID: mdl-29688843
17.
Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors.
Psychooncology
; 27(4): 1185-1192, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29315963
18.
A prospective study of docetaxel-associated pain syndrome.
Support Care Cancer
; 26(1): 203-211, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28733699
19.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28800861
20.
Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
Lancet Oncol
; 22(1): 27-28, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33387495